NCT03484299View on ClinicalTrials.gov

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Pancreas Cancer
Interventions
PROCEDURE

Irreversible Electroporation (IRE)

Non-thermal ablation of tumor

DRUG

Gemcitabine

25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled

DRUG

FOLFIRINOX

25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled

Trial Locations (1)

40202

RECRUITING

University of Louisville, Louisville

All Listed Sponsors
lead

University of Louisville

OTHER

NCT03484299 - Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter